Evidence map›Paper›PMID 31317035›Full record

ArticleBioMed research international2019

Tongxinluo Attenuates Myocardiac Fibrosis after Acute Myocardial Infarction in Rats via Inhibition of Endothelial-to-Mesenchymal Transition.

Yujie Yin, Qian Zhang, Qifei Zhao, Guoyuan Ding, Cong Wei, Liping Chang, Hongrong Li, Hongying Bei, Hongtao Wang, Junqing Liang and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. miR-325-3p Overexpression Inhibits Proliferation and Metastasis of Bladder Cancer Cells by Regulating MT3.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yujie YinGraduate School, Hebei University of Chinese Medicine, Shijiazhuang 050090, Hebei, China.ORCID https://orcid.org/0000-0002-9878-5568
Qian ZhangGraduate School, Hebei University of Chinese Medicine, Shijiazhuang 050090, Hebei, China.ORCID https://orcid.org/0000-0003-3356-1376
Qifei ZhaoGraduate School, Hebei Medical University, Shijiazhuang 050017, Hebei, China.ORCID https://orcid.org/0000-0002-9808-5684
Guoyuan DingKey Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, Hebei, China.ORCID https://orcid.org/0000-0001-5074-7506
Cong WeiKey Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, Hebei, China.ORCID https://orcid.org/0000-0003-4048-6124
Liping ChangKey Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, Hebei, China.ORCID https://orcid.org/0000-0001-6089-6767
Hongrong LiGraduate School, Hebei Medical University, Shijiazhuang 050017, Hebei, China.ORCID https://orcid.org/0000-0003-3426-6491
Hongying BeiDepartment of Cardiology, Affiliated Yiling Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050091, Hebei, China.ORCID https://orcid.org/0000-0002-7810-3320
Hongtao WangKey Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, Hebei, China.
Junqing LiangKey Laboratory of State Administration of Traditional Chinese Medicine (Cardio-Cerebral Vessel Collateral Disease), Shijiazhuang 050035, Hebei, China.ORCID https://orcid.org/0000-0002-7119-2236
Zhenhua JiaGraduate School, Hebei University of Chinese Medicine, Shijiazhuang 050090, Hebei, China.ORCID https://orcid.org/0000-0001-5132-1099
State Administration of Traditional Chinese Medicine of the People's Republic of China · CNHebei University of Chinese Medicine · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial-to-mesenchymal transition (EndMT) is an essential mechanism in myocardial fibrosis (MF). Tongxinluo (TXL) has been confirmed to protect the endothelium against reperfusion injury after acute myocardial infarction (AMI). However, whether TXL can inhibit MF after AMI via inhibiting EndMT remained unknown. This study aims to identify the role of EndMT in MF after AMI as well as the protective effects and underlying mechanisms of TXL on MF. The AMI model was established in rats by ligating left anterior descending coronary artery. Then, rats were administered with high- (0.8 g·kg

Indexed as

AnimalsCardiomyopathiesCell HypoxiaCoronary VesselsDisease Models, AnimalDrugs, Chinese HerbalEndothelial CellsEndotheliumFibrosisHumansMyocardial InfarctionMyocardiumPhosphatidylinositol 3-KinasesPhosphorylationRatsDrugs, Chinese HerbalPhosphatidylinositol 3-Kinasestongxinluo

Identifiers

PMID31317035
PMCPMC6601481
OpenAlexW2949807056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.